Blog
RSS FeedPosted by Michael Wonder on 10 Jun 2026
Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis
9 June 2026 - The MHRA has today authorised the medicine nipocalimab (Imaavy) to treat adults and adolescents aged 12 years ...
Posted by Michael Wonder on 06 Jun 2026
Adjuvanted trivalent influenza vaccine authorised for adults aged 50 and over
4 June 2026 - The MHRA has today granted a marketing authorisation for the adjuvanted trivalent influenza vaccine (Aujemflu) to protect ...
Posted by Michael Wonder on 05 Jun 2026
First new NHS treatment in over 20 years recommended for women with resistant ovarian cancer
4 June 2026 - The treatment uses a targeted therapy that seeks out a specific protein found on the surface of ...
Posted by Michael Wonder on 04 Jun 2026
Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis in adults
3 June 2026 - The MHRA has today authorised the medicine resmetirom (Rezdiffra) to treat adult patients with metabolic dysfunction-associated steatohepatitis. ...
Posted by Michael Wonder on 01 Jun 2026
Rilzabrutinib authorised to treat adults with immune thrombocytopenia when prior treatments have been insufficient
29 May 2026 - The MHRA has today granted a marketing authorisation for the medicines rilzabrutinib (Wayrilz) to treat adults with ...
Posted by Michael Wonder on 17 May 2026
MHRA approves beremagene geperpavec (Vyjuvek) for the treatment of dystrophic epidermolysis bullosa
15 May 2026 - The MHRA has today approved beremagene geperpavec (Vyjuvek) for the treatment of wounds in patients with dystrophic ...
Posted by Michael Wonder on 15 May 2026
Routine NHS access to spinal muscular atrophy treatments offers new hope for patients and families
14 May 2026 - People living with spinal muscular atrophy in England are set to gain routine access to two potentially ...
Posted by Michael Wonder on 15 May 2026
Over 1,500 people set to benefit from first immunotherapy for aggressive stomach cancer
14 May 2026 - Over 1,500 people set to benefit from first immunotherapy for aggressive stomach cancer. ...
Posted by Michael Wonder on 08 May 2026
NICE approves Duchenne muscular dystrophy treatment givinostat after commercial deal sealed
8 May 2026 - Around 530 people in England will benefit from access to the Duchenne muscular dystrophy treatment givinostat, following ...
Posted by Michael Wonder on 08 May 2026
MHRA approves donidalorsen (Dawnzera) for the treatment of hereditary angioedema
7 May 2026 - The MHRA has today approved donidalorsen (Dawnzera) for use in patients 12 years and older with hereditary angioedema to ...
Posted by Michael Wonder on 02 May 2026
MHRA approves Linerixibat (Lynavoy) for the treatment of itch due to biliary tract disease
1 May 2026 - The MHRA has today approved Linerixibat (Lynavoy) for use to treat an itch in adults with primary biliary cholangitis. ...
Posted by Michael Wonder on 30 Apr 2026
First NICE recommended treatment for uncontrolled generalised myasthenia gravis
29 April 2026 - We’ve recommended a new treatment called rozanolixizumab for some adults living with generalised myasthenia gravis whose ...
Posted by Michael Wonder on 23 Apr 2026
Enflonsia (clesrovimab-cfor) approved to prevent RSV in newborns and infants
22 April 2026 - The MHRA has today approved the medicine Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) ...
Posted by Michael Wonder on 22 Apr 2026
New life-extending treatment given the green light for people with rare form of bile duct cancer
21 April 2026 - A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended ...
Posted by Michael Wonder on 19 Apr 2026
New take at home drug recommended for people with chronic lymphocytic leukaemia
17 April 2026 - NICE has recommended a new take at home tablet for some people with chronic lymphocytic leukaemia whose ...